此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

QA102 干性 AMD 受试者的 II 期研究 (AMEND)

2026年9月8日 更新者:Smilebiotek Zhuhai Limited

一项 2 期、双盲、随机、安慰剂对照、剂量反应研究,评估 QA102 在干性年龄相关性黄斑变性 (AMD) 受试者中的安全性和有效性

This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.

研究概览

详细说明

Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.

研究类型

介入性

注册 (实际的)

150

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Phoenix、Arizona、美国、85021
        • Associated Retina Consultants
    • California
      • Mountain View、California、美国、94040
        • Northern California Retina Vitreous Associates Medical Group
      • Pasadena、California、美国、91107
        • California Eye Specialists Medical Group
      • Redlands、California、美国、91107
        • California Eye Specialists Medical Group
    • Colorado
      • Colorado Springs、Colorado、美国、80909
        • Retina Consultants of Southern Colorado, P.C.
    • Florida
      • Deerfield Beach、Florida、美国、33064
        • Advanced Research
      • Fort Myers、Florida、美国、33912
        • National Ophthalmic Research Institute
      • Miami、Florida、美国、33143
        • MedEye Associates
      • Pensacola、Florida、美国、32503
        • Retina Specialty Institute
      • Pinellas Park、Florida、美国、33782
        • Eye Associates of Pinellas
      • Sarasota、Florida、美国、34239
        • Sarasota Retina Institute
      • Winter Haven、Florida、美国、33880
        • Vitreous and Retina Consultants
    • Georgia
      • Marietta、Georgia、美国、30060
        • Marietta Eye Clinic
    • Illinois
      • Oak Forest、Illinois、美国、60452
        • University Retina and Macula Associates
    • Louisiana
      • West Monroe、Louisiana、美国、71291
        • Northeast Louisiana dba Haik Humble Eye Center
    • Maryland
      • Baltimore、Maryland、美国、21209
        • The Retina Care Center
      • Hagerstown、Maryland、美国、21740
        • Cumberland Valley Retina Consultants
      • Hagerstown、Maryland、美国、21740
        • Mid Atlantic Retina Specialists
    • Massachusetts
      • Worcester、Massachusetts、美国、01605
        • Vitreo-Retinal Associates, P.C.
    • Missouri
      • St Louis、Missouri、美国、63144
        • Retina Research Institute
    • Ohio
      • Cincinnati、Ohio、美国、45202
        • Velocity Clinical Research
    • Oregon
      • Eugene、Oregon、美国、97401
        • Verum Research, LLC
    • Pennsylvania
      • Erie、Pennsylvania、美国、16507
        • Erie Retina Research
    • Texas
      • Abilene、Texas、美国、79606
        • Retina Research Institute of Texas
      • Austin、Texas、美国、78705
        • Austin Research Center for Retina
      • Dallas、Texas、美国、75243
        • AXIS Clinicals LLC / Retina of North Texas
      • Plano、Texas、美国、75075
        • Texas Retina Associates - Plano
      • San Antonio、Texas、美国、78215
        • San Antonio Eye Center
    • Utah
      • Salt Lake City、Utah、美国、84107
        • Rocky Mountain Retina Consultants

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Subject must be able to understand and willing to sign a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
  • Subject must be age ≥50 years at the time of informed consent.
  • Subject must be able to take oral medications and willing to record daily adherence to taking their assigned capsules.
  • Subject must have adequate hematologic function, hepatic function, renal function and coagulation profile as defined in the protocol.
  • Subject must be willing and able to comply with study procedures and examinations.

Specific to the Study Eye:

  • Subject must have one of the following:

    • extensive intermediate-size drusen, or at least 1 large drusen, or
    • GA ((not involving the foveal center point) secondary to AMD, with very limited aggregate size of total GA(s), as defined in the protocol.
  • Subject must be able to correctly identify ≥35 ETDRS letters (approximately 20/200 Snellen equivalent).

Specific to Fellow Eye:

- Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.

Specific to Both Eyes:

- Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.

Key Exclusion Criteria:

  • Subject received an active investigational drug within 6 weeks (or 5 half-lives of the active, whichever is longer) prior to screening for this QA102 study.
  • Subject has ever received gene therapy (for any condition).
  • Subject is unwilling to stop intake of Age-Related Eye Disease Studies (AREDS) vitamins for the duration of the study.
  • Subject has a clinically significant systemic disease that might interfere with the study, in the judgment of the Investigator.
  • Subject had major surgery within 30 days prior to Screening.

Specific to Study Eye:

  • Subject has large GA, subfoveal GA, or active or inactive CNV, as confirmed by the CRC.
  • Subject has GA or CNV due to causes other than AMD that that developed between Visit 1 (Screening) and Visit 2 (Randomization).
  • Subject has endophthalmitis.
  • Subject has a hemorrhagic or serous pigment epithelial detachment (PED) within 500 µm of the foveal center point, to be confirmed by the CRC.
  • Subject has had retinal procedures or surgeries, or has a retinal pathology, such as a macular hole.
  • Subject has aphakia or absence of the posterior capsule.
  • Subject has ever received, whether in an interventional trial or by prescription, an FDA- approved treatment for GA. Use of such treatment during the QA102 study period also is prohibited. (Study Eye Only)

Specific to Fellow Eye:

Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.

Specific to Either Eye:

  • Subject had intraocular surgery with lens replacement within 3 months of Screening.
  • Subject has any ophthalmic condition that could require surgery during the study period.
  • Subject has an ocular condition that might affect adequate imaging of the retina and/or or alter visual acuity.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:QA102 200mg group

Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months

Capsules

实验性的:QA102 400mg group

Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months

Capsules

安慰剂比较:Placebo group

Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months

Capsules

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change From Baseline in Soft Drusen Volume (mm3)
大体时间:Month 12

Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set

Month 12

次要结果测量

结果测量
措施说明
大体时间
Mean Rate of GA Growth
大体时间:Month 12

Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline

Month 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年9月22日

初级完成 (实际的)

2024年11月12日

研究完成 (实际的)

2024年11月12日

研究注册日期

首次提交

2022年9月8日

首先提交符合 QC 标准的

2022年9月8日

首次发布 (实际的)

2022年9月13日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月8日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • QA102-CS201

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅